Study Sample 113 patients were enrolled via patient support groups and via study investigating oncologists. After excluding patients, who withdrew their informed consent or who provided inconsistent/incomplete interview data, 84 patients were included in the analyses. Of these, 36.9% were female, mean age was 62.75 years and mean disease duration of MM (since time of diagnosis) was 5.51 years. Most of the patients currently received a treatment for their RRMM at the time of the interview (65.5%). The DCE was performed in two stages. First, in a qualitative pre-study based on discussions in two small focus groups of RRMM patients, a DCE questionnaire was developed which was then tested for feasibility. In a second step, we conducted our main quantitative study to investigate patient preferences. In a German cross-sectional survey, patients were interviewed by experienced and trained interviewers, either face-to-face or via telephone to collect the DCE data. Attributes describing real-world treatment of RRMM included in the DCE were: Drug administration -application 1: tablet once/day + once/week, 2-hour physician visit once/month versus -application 2: tablet once/day + twice/week, 2-hour physician visit once/month versus -application 3: tablet once/day + once/week, physician visit twice/week lasting 3-4 hours incl. infusion Time without disease progression:
-26 months versus -20 months versus -17 months Possibility of side effects affecting the blood: -12% versus -19% Possibility of heart failure:
In a conditional logit regression model, the influence of different attribute levels on the probability of a patient deciding to choose a specific treatment option were estimated. Estimated marginal utilities for each attribute level were used to quantify the relative importance of each attribute in the patient's decision for or against a treatment option.
CONCLUSION AND RECOMMENDATIONS
RRMM patients prefer treatment options with an all-oral application mode, a longer disease-progression-free time and a lower probability of side effects. In order to receive a more convenient therapy, patients are willing to accept slightly less efficacy. To find the best therapy for each individual patient, the preferences of a patient should play a key role in the decision process. Results obtained from this study present important insights into RRMM patient preferences. Those preferences should be taken into consideration by treating physicians whenever a decision regarding RRMM treatment has to be made. Importance of attributes "Therapy regimen/drug administration" and "Time without progression of disease" were the attributes that were given the most weight by the patients, with 38.83% and 38.63% importance for the overall decision of patients for or against a treatment option. Generally, the attributes "Possibility of side effect heart failure" (13.92%) and "Possibility of side effects affecting the blood" (8.62%) were ranked less important.
Figure 1 displays the patient preferences based on the a priori planned subgroup analyses. Older patients rated "Therapy regimen/drug administration" as most important attribute (>63.5 years: 40.07%; >75 years: 45.41%), while younger patients assigned the highest importance to "Time without progression of disease" (≤ 63.5 years: 42.32%; ≤ 75 years: 39.21%). Men considered "Therapy regimen/drug administration" as most important (39.20%), while women weighted time without progression as highest attribute (43.20%).
Patients with a longer disease duration/a longer distance to their treating physician rated "Therapy regimen" as most important (39.32%/42.14%), while patients with a shorter disease duration/a shorter distance to their treating physician rated "Time without disease progression" as most important (39.75%/38.73%).
Utility analysis With regard to the attribute "Therapy regimen/drug administration", patients preferred Application 1 and 2 over Application 3 (utility 1.713/1.434 vs. 0.00). Furthermore, patients preferred longer progression free time and lower probabilities of adverse events. When the derived utility values of different treatment attributes were transferred to existing RRMM treatment options, the highest overall utility for patients proved to arise from the treatment regimen Ixazomib+Lenalidomide+Dexamethasone (utility: 3.218 to 3.708, depending on the assumed side effect probabilities). 
